Alnylam Pharmaceuticals (ALNY) Return on Capital Employed Growth (3y) (2013 - 2026)
Alnylam Pharmaceuticals (ALNY) Return on Capital Employed Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 4,893.00 |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -494.00 |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -649.00 |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -3,782.00 |
| 10 | Alnylam Pharmaceuticals | 37.29 Bn | 34.28 Bn | 959.66 Mn | 4,853.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4,853.00 |
| Dec 31, 2025 | 4,288.00 |
| Sep 30, 2025 | 3,813.00 |
| Jun 30, 2025 | 2,040.00 |
| Mar 31, 2025 | 1,916.00 |
| Dec 31, 2024 | 1,893.00 |
| Sep 30, 2024 | 1,808.00 |
| Jun 30, 2024 | 3,017.00 |
| Mar 31, 2024 | 2,227.00 |
| Dec 31, 2023 | 2,004.00 |
| Sep 30, 2023 | 1,932.00 |
| Jun 30, 2023 | 613.00 |
| Mar 31, 2023 | 1,988.00 |
| Dec 31, 2022 | 1,609.00 |
| Sep 30, 2022 | 812.00 |
| Jun 30, 2022 | 1,796.00 |
| Mar 31, 2022 | 2,921.00 |
| Dec 31, 2021 | 3,159.00 |
| Sep 30, 2021 | 2,144.00 |
| Jun 30, 2021 | 858.00 |